Last reviewed · How we verify
pemetrexed plus cisplatin — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
pemetrexed plus cisplatin (pemetrexed plus cisplatin) — Chinese Academy of Medical Sciences.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| pemetrexed plus cisplatin TARGET | pemetrexed plus cisplatin | Chinese Academy of Medical Sciences | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- pemetrexed plus cisplatin CI watch — RSS
- pemetrexed plus cisplatin CI watch — Atom
- pemetrexed plus cisplatin CI watch — JSON
- pemetrexed plus cisplatin alone — RSS
Cite this brief
Drug Landscape (2026). pemetrexed plus cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/pemetrexed-plus-cisplatin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing